Medications

How a novel drug pushes the HIV capsid to breaking point

Just over a year ago, the European Union and the US Food and Drug Administration approved a new anti-retroviral drug to treat human immunodeficiency virus (HIV) infections. Lenacapavir is the first drug available to patients ...

Immunology

Reviewing new challenges and opportunities for hepatitis B cures

Hepatitis B virus (HBV) is a significant public health problem, with over 296 million people chronically infected worldwide. Despite the availability of a safe and effective vaccine for over 40 years, HBV remains a leading ...

Diseases, Conditions, Syndromes

Infectious Diseases Society of America meeting, some highlights

The annual meeting of the Infectious Diseases Society of America was held this year from Oct. 11 to 15 in Boston and attracted participants from around the world, including scientists, physicians, and other health care professionals.

Neuroscience

'Viral relicts' in the genome could fuel neurodegeneration

Genetic remnants of viruses that are naturally present in the human genome could affect the development of neurodegenerative diseases. Researchers at DZNE have come to this conclusion based on studies of cell cultures. In ...

Genetics

SARS-CoV-2: The grasping fingers of the viral N protein

Immediately after the infection of a cell in the throat or lungs, the SARS-CoV-2 virus works very hard to replicate, using the human cell's metabolic pathways to produce its proteins and make sure that its genetic material ...

Diseases, Conditions, Syndromes

Tracking SARS-CoV-2 in Mozambique

A new study co-led by ISGlobal, the Manhiça Health Research Centre (CISM) and the Instituto de Biomedicina de Valencia (IBV), used cutting-edge sequencing technology and phylogenetic analysis to study the second and third ...

page 1 from 12